Generic Product News

Azurette (Desogestrel/Ethinyl Estradiol and Ethinyl Estradiol Tablets)

Marketed by:

Watson Pharmaceuticals Inc (Corona, CA)

Compared to:

Mircette (Duramed Pharmaceuticals Inc)

Indication:

December 29, 2008?Watson Pharmaceuticals Incannounced that its subsidiary, Watson LaboratoriesInc, received final FDA approval for its abbreviated new drug application for desogestrel/ethinylestradiol and ethinyl estradiol tablets USP, 0.15mg/0.02 mg. Desogestrel/ethinyl estradiol andethinyl estradiol tablets USP is the generic equivalentto Duramed Pharmaceuticals Inc?s Mircettelow-dose monthly oral contraceptive product,which is indicated for the prevention of pregnancy.

Dosage Form:

Tablets: each white tablet contains 0.15 mg desogestreland 0.02 mg ethinyl estradiol; each green tablet containsinert ingredients; each blue tablet contains 0.01 mg ethinylestradiol.

For More Information:

www.watson.com

Cefadroxil Capsules, 500 mg

Marketed by:

Greenstone LLC(Peapack, NJ)

Compared to:

Duricef (Warner Chilcott)

Indication:

December 11, 2008?Greenstone LLC, Pfizer?s genericsubsidiary, introduced Cefadroxil Capsules, 500 mg toits product line. Cefadroxil capsules are indicated for the treatment of patients with infection caused by susceptiblestrains of organisms in the following diseases:urinary tract infections, skin and skin structure infections,and pharyngitis and/or tonsillitis. The capsules arecontraindicated in patients with known allergy to thecephalosporin group of antibiotics.

Dosage Form:

Capsules: 500 mg

For More Information:

www.greenstonellc.com

Fentanyl Transdermal System, CII

Marketed by:

Teva Pharmaceuticals(North Wales, PA)

Compared to:

Duragesic TransdermalSystem (Johnson &Johnson Corp)

Indication:

October 23, 2008?Teva Pharmaceuticals announcedthe introduction and availability of Fentanyl TransdermalSystem, CII. This product is AB-rated to DuragesicTransdermal System. It is indicated for the managementof persistent, moderate-to-severe chronic pain thatrequires continuous opioid administration for an extendedperiod of time and cannot be managed by othermeans, such as nonsteroidal analgesics, opioid combinationproducts, or immediate-release opioids. Doses mustbe individualized based on the status of each patient andshould be assessed at regular intervals after application.

Dosage Form:

25, 50, 75, and 100 mcg/hour

For More Information:

www.tevausa.com

888-TEVA USA (888-838-2872)

Kionex (Sodium Polystyrene Sulfonate Suspension, USP) 15 g/60 mL

Marketed by:

Paddock Laboratories Inc (Minneapolis, MN)

Compared to:

SPS Suspension (Carolina Medical Products)

Indication:

December 30, 2008?Paddock Laboratories Incannounced the launch of Kionex 15 g/60 mL, which isAA-rated to SPS Suspension. This product is indicatedfor the treatment of hyperkalemia. Kionex can be administeredorally or in an enema. The average adult dose is15 g (60 mL) to 60 g (240 mL) of suspension. This is bestprovided by administering 15 g of Kionex suspension 1to 4 times daily.

Dosage Form:

480 mL and unit-dose 60 mL

For More Information:

www.paddocklabs.com

800-328-5113